LXRX NASDAQ
Lexicon Pharmaceuticals, Inc.
1W: +1.1%
1M: -18.8%
3M: -21.6%
YTD: +51.7%
1Y: +59.6%
3Y: +5.2%
5Y: -46.8%
$1.82
+0.00 (+0.00%)
Weekly Expected Move ±8.3%
$2
$2
$2
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.67
Bullish
3 bullish
1 neutral
0 bearish
Articles (7d)
4
Daily Sentiment (7 Days)
Articles (63)
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Gap Up – Here’s What Happened
Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today
Lexicon a new overweight at Cantor on optimism for Inpefa in cardiomyopathy
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Average Recommendation of “Hold” from Brokerages
Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851
Lexicon (LXRX) Q2 2026 Earnings Call Transcript
Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Misses Revenue Estimates
Here's Why You Should Add LXRX Stock to Your Portfolio Now
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?
Lexicon (LXRX) Q1 2026 Earnings Transcript
Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
12 Health Care Stocks Moving In Monday's Intraday Session
Lexicon anticipates SONATA-HCM enrollment completion by mid-2026 while highlighting $100m Hercules debt facility
Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1
Lexicon Pharmaceuticals reports Q1 results
Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates
Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates
Lexicon Pharmaceuticals Q1 2026 Earnings Preview
Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital
Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Passes Above 200-Day Moving Average – What’s Next?
Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting
Lexicon Pharmaceuticals (NASDAQ:LXRX) Reaches New 1-Year High – Should You Buy?
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Passes Above Two Hundred Day Moving Average – What’s Next?
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Passes Above Two Hundred Day Moving Average – Here’s Why
Avis Budget Group, Toyota Motor And Other Big Stocks Moving Lower In Monday's Pre-Market Session
LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug
Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Crosses Above Two Hundred Day Moving Average – Here’s What Happened
Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes
XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study
What is HC Wainwright’s Estimate for LXRX Q1 Earnings?
What is HC Wainwright’s Estimate for LXRX FY2027 Earnings?
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Up 5.8% Following Strong Earnings
Lexicon outlines 2026 milestones as SONATA-HCM enrollment surpasses 50% and cash position is strengthened
Lexicon (LXRX) Q4 2025 Earnings Call Transcript
Lexicon Pharmaceuticals GAAP EPS of -$0.04 beats by $0.03, revenue of $5.49M beats by $2.35M
Lexicon Pharmaceuticals Q4 Earnings Summary & Key Takeaways
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates
Earnings Scheduled For March 5, 2026
Here are the major earnings before the open Thursday
Lexicon Pharmaceuticals Q4 2025 Earnings Preview
Exploring Lexicon Pharmaceuticals's Earnings Expectations
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates
Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences
Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026
Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
Invus Global Management, Llc Purchases 1,538,462 Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
Lexicon Announces Proposed Public Offering of Common Stock
Financial Contrast: NovAccess Global (OTCMKTS:XSNX) vs. Lexicon Pharmaceuticals (NASDAQ:LXRX)
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain
Lexicon Pharmaceuticals, Inc. (LXRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference
Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”
Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum
Lexicon Pharmaceuticals Has Multiple Paths To Upside, But Formidable Hurdles As Well
Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences
Lexicon Pharmaceuticals, Inc. (LXRX) Presents at Jefferies London Healthcare Conference 2025 Transcript